Skip to content

Clinical Study of Xingnao Zhitong Pills in the Prevention and Treatment of Migraine (Wind-Blood Stasis Obstructing Collaterals Syndrome): A Single-Arm, Self-Controlled Design

Clinical Study of Xingnao Zhitong Pills in the Prevention and Treatment of Migraine (Wind-Blood Stasis Obstructing Collaterals Syndrome): A Single-Arm, Self-Controlled Design

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000626
Enrollment
Unknown
Registered
2026-03-19
Start date
2026-04-10
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Interventions

Treatment group:Xingnao Zhitong Pills

Sponsors

Hunan Provincia Hospital of Integrated Traditional Chinese and Western Medicine ( The Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Age between 18 and 65 years old, with migraine onset before the age of 50; (2) Meet the diagnostic criteria for migraine with or without aura as per the Chinese Guidelines for Migraine Diagnosis and Treatment, with a history of =12 months; (3) Comply with the above TCM syndrome differentiation criteria; (4) Experience =2 migraine attacks per month in the past 3 months; (5) The patient or their legal representative voluntarily participates in the trial and signs the informed consent form.

Exclusion criteria

Exclusion criteria: (1) A history of inadequate response to three or more drugs used for migraine preventive treatment; (2) Use of prohibited substances or opioids (such as morphine, oxycodone, fentanyl, etc.); (3) Diagnosis of major depressive disorder (Hamilton Depression Rating Scale HAMD-17 score = 24).

Design outcomes

Primary

MeasureTime frame
Changes in the average monthly migraine days from baseline during the 12-week treatment period.;

Secondary

MeasureTime frame
Proportion of subjects achieving a =50% reduction in migraine days;Change from baseline in the average migraine pain intensity (VAS) score;Effect of Xingnao Zhitong Pills on the frequency of acute-phase analgesic use;Change from baseline in the patient's quality of life (HIT-6) score;Change from baseline in the Migraine Disability Assessment (MIDAS) score;Change from baseline in the Traditional Chinese Medicine syndrome efficacy score;Proportion of adverse events;

Countries

China

Contacts

Public ContactXie le

Hunan Provincia Hospital of Integrated Traditional Chinese and Western Medicine ( The Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine)

1289398706@qq.com13548659005

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026